How a drug rep dealt with concerns that Zyprexa (olanzapine) causes obesity and diabetes: A video interview.

As an M.D. and pharmacology instructor I strongly believe that it’s really important that prescribers know the backstage of the pharmaceutical industry.

In this video produced by PharmedOut, Shahram Ahari, a former drug rep from Eli Lilly; talks about the tactics he and his colleagues were instructed. The target was clear: to sell olanzapine (Zyprexa) despite of clinical concerns about two side effects: diabetes and obesity.

More information on drug rep tactics can be found on the following paper published in PLoS Medicine:

Following the Script: How Drug Reps Make Friends and Influence Doctors

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.




Are you a visual learner interested in learning psychopharmacology? Click here to get our videos